Grifols (NASDAQ:GRFS) Trading Down 3.7% – Here’s Why

Grifols, S.A. (NASDAQ:GRFS)’s stock price fell 3.7% during trading on Friday . The company traded as low as $7.16 and last traded at $7.20. 616,128 shares changed hands during trading, a decline of 10% from the average session volume of 683,670 shares. The stock had previously closed at $7.47.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank upgraded shares of Grifols to a “strong-buy” rating in a report on Tuesday, October 29th.

Grifols Stock Down 1.0 %

The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. The stock’s fifty day simple moving average is $7.71 and its 200 day simple moving average is $8.20.

Hedge Funds Weigh In On Grifols

Several hedge funds have recently modified their holdings of the stock. Brandes Investment Partners LP lifted its holdings in shares of Grifols by 8.7% in the 2nd quarter. Brandes Investment Partners LP now owns 18,596,790 shares of the biotechnology company’s stock valued at $117,242,000 after buying an additional 1,481,924 shares during the period. Armistice Capital LLC grew its stake in shares of Grifols by 18.7% during the 2nd quarter. Armistice Capital LLC now owns 7,892,000 shares of the biotechnology company’s stock worth $49,759,000 after purchasing an additional 1,244,000 shares during the period. Whitebox Advisors LLC increased its holdings in shares of Grifols by 56.2% during the 3rd quarter. Whitebox Advisors LLC now owns 4,221,483 shares of the biotechnology company’s stock valued at $37,487,000 after purchasing an additional 1,519,093 shares in the last quarter. Sei Investments Co. lifted its stake in shares of Grifols by 4.7% in the 2nd quarter. Sei Investments Co. now owns 2,209,547 shares of the biotechnology company’s stock valued at $13,931,000 after purchasing an additional 100,131 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in Grifols by 144.0% during the third quarter. JPMorgan Chase & Co. now owns 2,002,511 shares of the biotechnology company’s stock worth $17,782,000 after buying an additional 1,181,959 shares in the last quarter.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.